Novavax’s Updated Covid Vaccine Approved by FDA for Emergency Use

The Food and Drug Administration has granted emergency use authorization to Novavax’s updated Covid vaccine, paving the way for its rollout in the United States. This approval comes shortly after Pfizer and Moderna’s new vaccines were made available to Americans. Novavax’s single-strain vaccine, specifically targeting the omicron subvariant XBB.1.5, awaits a recommendation from the Centers for Disease Control and Prevention before it can be accessed by patients at various distribution sites. The CDC is expected to provide its endorsement soon.

Novavax’s vaccine, which employs protein-based technology, offers an alternative for individuals who prefer not to receive messenger RNA shots from Pfizer and Moderna. Public health officials believe that having non-mRNA vaccine options available is crucial. All three vaccines are anticipated to assist the United States in combating the spread of Covid during the fall and winter seasons, when the virus tends to circulate more actively.

While the current surge in cases and hospitalizations remains lower than previous waves, it has prompted the reintroduction of mask mandates in certain businesses and schools. The rise is attributed to newer strains of the virus, including the omicron strain EG.5 or Eris, which accounts for a significant portion of cases. Novavax’s new vaccine has demonstrated a broad immune response against Eris and another fast-spreading strain called XBB.1.16.6, both descendants of omicron.

However, it is uncertain whether Novavax’s vaccine will protect against the highly mutated omicron strain BA.2.86, which health officials are closely monitoring. Novavax is currently testing its vaccine against this variant. The release of Novavax’s updated shot marks the end of the U.S. Covid public health emergency. As a result, all three manufacturers will sell their vaccines directly to healthcare providers and compete for commercial market share.

Novavax’s vaccine has a list price of $130 per dose, and federal and corporate programs aim to provide vaccines at no cost to uninsured and underinsured individuals. The Biden administration’s Bridge Access Program is one such initiative. While it remains to be seen how many Americans will choose to receive the new vaccines, a CDC survey conducted in August indicated that approximately 42% of respondents were likely to get a Covid shot during the fall.

As the nation continues to grapple with the ongoing pandemic, the approval of Novavax’s updated Covid vaccine offers another tool in the fight against the virus. With multiple options available, individuals can make informed choices based on their preferences and medical needs.